SG96535A1 - Pharmaceutical composition for the treatment or prevention of a malignant tumor - Google Patents

Pharmaceutical composition for the treatment or prevention of a malignant tumor

Info

Publication number
SG96535A1
SG96535A1 SG9608518A SG1996008518A SG96535A1 SG 96535 A1 SG96535 A1 SG 96535A1 SG 9608518 A SG9608518 A SG 9608518A SG 1996008518 A SG1996008518 A SG 1996008518A SG 96535 A1 SG96535 A1 SG 96535A1
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
polypeptide
prevention
treatment
antibody
Prior art date
Application number
SG9608518A
Other languages
English (en)
Inventor
Pierre Chambon
Marie-Paule Kieny
Richard Lathe
Mara Hareuveni
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of SG96535A1 publication Critical patent/SG96535A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG9608518A 1990-10-23 1991-10-23 Pharmaceutical composition for the treatment or prevention of a malignant tumor SG96535A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013101A FR2668064B1 (fr) 1990-10-23 1990-10-23 Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Publications (1)

Publication Number Publication Date
SG96535A1 true SG96535A1 (en) 2003-06-16

Family

ID=9401474

Family Applications (1)

Application Number Title Priority Date Filing Date
SG9608518A SG96535A1 (en) 1990-10-23 1991-10-23 Pharmaceutical composition for the treatment or prevention of a malignant tumor

Country Status (12)

Country Link
US (3) US5861381A (ja)
EP (1) EP0554344B1 (ja)
JP (1) JP3195958B2 (ja)
AT (1) ATE169640T1 (ja)
CA (1) CA2094705C (ja)
DE (1) DE69129989T2 (ja)
DK (1) DK0554344T3 (ja)
ES (1) ES2121791T3 (ja)
FR (1) FR2668064B1 (ja)
HK (1) HK1012841A1 (ja)
SG (1) SG96535A1 (ja)
WO (1) WO1992007000A1 (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
ATE152915T1 (de) * 1991-11-29 1997-05-15 Viagene Inc Immuntherapeutische vektorkonstrukte gegen krebs
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000026340A2 (en) * 1998-11-03 2000-05-11 The Penn State Research Foundation Novel nucleic acid molecules encoding opioid growth factor receptors
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
PT1210430E (pt) * 1999-09-08 2006-12-29 Imp Cancer Res Tech Péptidos derivados de muc-1
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
KR20030068536A (ko) * 2000-09-11 2003-08-21 다나-파버 캔서 인스티튜트 Ｍｕｃ1 세포외 도메인 및 이로부터 유래된 암 치료조성물과 방법
EP2322929B1 (en) 2000-11-27 2016-04-06 Minerva Biotechnologies Corporation diagnostics, drug screening and treatment for cancer
EP1531842A4 (en) * 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc REGULATION OF CELL GROWTH BY MUC1
WO2002078607A2 (en) * 2001-04-02 2002-10-10 The University Of Miami Mucin peptide with immunoenhancing properties
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
JP3854905B2 (ja) * 2002-07-30 2006-12-06 株式会社 日立ディスプレイズ 液晶表示装置
EP2363410B1 (en) * 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation Isoforms of MUC1
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
ES2359473T3 (es) 2003-07-21 2011-05-23 Transgene S.A. Citoquinas multifuncionales.
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
AU2004299457B2 (en) * 2003-12-12 2011-03-24 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
EP1718367A1 (en) * 2004-02-23 2006-11-08 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
WO2008011672A1 (en) * 2006-07-25 2008-01-31 4G Vaccines Pty Ltd A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
WO2008097844A2 (en) * 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US20110287089A1 (en) 2009-01-13 2011-11-24 Karola Rittner Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
EP2382474B1 (en) 2009-01-20 2015-03-04 Transgene SA Soluble icam-1 as biomarker for prediction of therapeutic response
SG2014014021A (en) 2009-03-24 2014-07-30 Transgene Sa Biomarker for monitoring patients
NZ594896A (en) 2009-04-17 2013-07-26 Transgene Sa Biomarker for monitoring patients
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
TW201109440A (en) 2009-07-21 2011-03-16 Transgene Sa Enzymatic composition for the digestion of chicken embryos
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
US10517943B2 (en) 2014-12-01 2019-12-31 Transgene S.A. Stable liquid vaccinia virus formulations
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174534A1 (en) * 1984-08-22 1986-03-19 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02501828A (ja) * 1987-01-07 1990-06-21 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド プローブ
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
SE459115B (sv) * 1987-10-08 1989-06-05 Gas Control Equipment Ab Anordning i ventil foer gasbehaallare
EP0442926A1 (en) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
ZA898777B (en) * 1988-11-17 1990-12-28 Univ Melbourne Monoclonal antibodies
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174534A1 (en) * 1984-08-22 1986-03-19 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies

Also Published As

Publication number Publication date
FR2668064A1 (fr) 1992-04-24
DK0554344T3 (da) 1999-05-17
EP0554344A1 (fr) 1993-08-11
FR2668064B1 (fr) 1994-12-16
WO1992007000A1 (fr) 1992-04-30
DE69129989T2 (de) 1999-04-08
US5861381A (en) 1999-01-19
CA2094705A1 (fr) 1992-04-24
DE69129989D1 (de) 1998-09-17
US6203795B1 (en) 2001-03-20
ATE169640T1 (de) 1998-08-15
US6328956B1 (en) 2001-12-11
JPH06502399A (ja) 1994-03-17
JP3195958B2 (ja) 2001-08-06
EP0554344B1 (fr) 1998-08-12
CA2094705C (fr) 2007-05-15
HK1012841A1 (en) 1999-08-06
ES2121791T3 (es) 1998-12-16

Similar Documents

Publication Publication Date Title
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
CA2072249A1 (en) Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
NZ232554A (en) 100,000 dalton tumour cell glycoprotein antigen (l45), monoclonal antibodies thereto and medicaments
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
GB9206422D0 (en) Antibody preparation
IT8367525A0 (it) Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
MX9804358A (es) Apoptosis inducida por el anticuerpo monoclonal anti-her2.
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
GB2270078B (en) Minimum recognition unit of a pem mucin tandem repeat specific monoclonal antibody
EP0739350A4 (en) LIGAND FIXING FAS ANTIGEN
IL187595A (en) Pharmaceutical preparation containing monoclonal antibody - tumors and production
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
ES8800604A1 (es) Un metodo para producir anticuerpos monoclonales
CA2013544A1 (en) Retinoblastoma gene product antibodies and uses therefor
AU5752490A (en) A novel tumor associated antigen
AU5790390A (en) A novel tumor associated antigen